Analysts Set Smith & Nephew plc (LON:SN) Price Target at GBX 1,382.62

Smith & Nephew plc (LON:SN) has been given a consensus rating of “Hold” by the eight brokerages that are currently covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is GBX 1,382.62.

Several research firms have recently commented on SN. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 1,400 price target on shares of Smith & Nephew in a research report on Thursday, June 11th. Royal Bank Of Canada restated a “sector perform” rating and set a GBX 1,350 target price on shares of Smith & Nephew in a research report on Monday, June 29th. UBS Group reiterated a “neutral” rating and issued a GBX 1,300 price target on shares of Smith & Nephew in a research report on Tuesday, May 5th. Berenberg Bank reiterated a “hold” rating and set a GBX 13 price target on shares of Smith & Nephew in a research note on Friday, May 1st. Finally, Jefferies Financial Group reissued a “buy” rating and set a GBX 2,760 price objective on shares of Smith & Nephew in a research report on Thursday, May 21st.

Smith & Nephew Stock Performance

Smith & Nephew stock opened at GBX 1,141.50 on Friday. The firm’s 50 day moving average price is GBX 1,127.74 and its two-hundred day moving average price is GBX 1,206.32. The company has a debt-to-equity ratio of 62.90, a quick ratio of 0.84 and a current ratio of 2.57. The stock has a market capitalization of £12.51 billion, a PE ratio of 41.10, a PEG ratio of 0.46 and a beta of 0.68.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.